Monday, 21 November 2011

Actos


Actos is a brand name of pioglitazone, approved by the FDA in the following formulation(s):


ACTOS (pioglitazone hydrochloride - tablet; oral)



  • Manufacturer: TAKEDA PHARMS NA

    Approval date: July 15, 1999

    Strength(s): EQ 15MG BASE, EQ 30MG BASE, EQ 45MG BASE [RLD]

Has a generic version of Actos been approved?


No. There is currently no therapeutically equivalent version of Actos available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Actos. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pharmaceutical composition
    Patent 5,965,584
    Issued: October 12, 1999
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES




  • Pharmaceutical composition
    Patent 6,150,383
    Issued: November 21, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,150,384
    Issued: November 21, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE




  • Pharmaceutical composition
    Patent 6,166,042
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE




  • Pharmaceutical composition
    Patent 6,166,043
    Issued: December 26, 2000
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS




  • Pharmaceutical composition
    Patent 6,172,090
    Issued: January 9, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS




  • Pharmaceutical composition
    Patent 6,211,205
    Issued: April 3, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,271,243
    Issued: August 7, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION




  • Pharmaceutical composition
    Patent 6,303,640
    Issued: October 16, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • August 9, 2016
      ✓ 
      Patent use: METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER




  • Pharmaceutical composition
    Patent 6,329,404
    Issued: December 11, 2001
    Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
    Assignee(s): Takeda Chemical Industries, Ltd.
    Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES



See also...

  • Actos Consumer Information (Drugs.com)
  • Actos Consumer Information (Wolters Kluwer)
  • Actos Consumer Information (Cerner Multum)
  • Actos Advanced Consumer Information (Micromedex)
  • Actos AHFS DI Monographs (ASHP)
  • Pioglitazone Consumer Information (Wolters Kluwer)
  • Pioglitazone Consumer Information (Cerner Multum)
  • Pioglitazone Advanced Consumer Information (Micromedex)
  • Pioglitazone Hydrochloride AHFS DI Monographs (ASHP)
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)